Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.068 AUD | -2.86% | +4.62% | +209.09% |
Apr. 30 | Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury | MT |
Apr. 18 | Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024 |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Drug Development
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | +36.40% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | +36.40% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
James Bonnar
CEO | Chief Executive Officer | - | 18-01-31 |
Founder | - | 17-08-28 | |
Chief Tech/Sci/R&D Officer | - | - | |
Benjamin Evison
CTO | Chief Tech/Sci/R&D Officer | - | 17-08-28 |
Investor Relations Contact | - | 23-05-31 | |
David Franks
SEC | Corporate Secretary | 53 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | - | 17-08-28 | |
Ruediger Weseloh
BRD | Director/Board Member | - | 19-05-31 |
Marcus Frampton
BRD | Director/Board Member | 44 | 19-05-31 |
John Moore
CHM | Chairman | 59 | 19-07-15 |
Christopher Cox
BRD | Director/Board Member | 59 | 19-10-31 |
Ian Dixon
BRD | Director/Board Member | - | 20-08-31 |
Gisela Mautner
BRD | Director/Board Member | - | 22-07-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 156,008,700 | 111,042,692 ( 71.18 %) | 0 | 71.18 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+209.09% | 8.15M | |
+37.78% | 705B | |
+32.82% | 583B | |
-3.51% | 364B | |
+19.94% | 332B | |
+5.14% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+9.32% | 169B |
- Stock Market
- Equities
- NYR Stock
- Company Nyrada Inc.